MTE26.02 EGFR Targeted Therapies: Lessons Learned
نویسندگان
چکیده
منابع مشابه
EGFR-targeted therapies in colorectal cancer.
The management of colorectal cancer relies heavily on the combination of the pyrimidine analog antimetabolite 5-fluorouracil with the platinum-based drug oxaliplatin or the topoisomerase inhibitor irinotecan. Optimization of dosing and scheduling of these agents to improve response and survival continues to evolve. Meanwhile, the rational targeting of molecular signaling pathways that are invol...
متن کاملNeurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium.
The North American Brain Tumor Consortium (NABTC) is a multi-institutional consortium with the primary objective of evaluating novel therapeutic strategies through early phase clinical trials. The NABTC has made substantial changes to the design and methodology of its trials since its inception in 1994. These changes reflect developments in technology, new types of therapies, and advances in ou...
متن کاملCurrent Molecularly Targeted Therapies against EGFR for Cancer
Epidermal Growth Factor Receptor (EGFR) is a Tyrosine Kinase cell surface receptor (RTK) that is expressed in more than 60% of Non-Small Cell Lung Carcinomas (NSCLC) [1], 60-80% of metastatic colorectal cancers (mCRC) [2] and 80-90% of head and neck squamous cell cancer (HNSCC) [3]. EGFR overexpression activates multiple downstream pathways such as PI3K-AKT-mTOR and RAS-RAFMEK-ERK which are inv...
متن کاملClinical Significance of Skin Toxicity due to EGFR-Targeted Therapies
Many small molecules and monoclonal antibodies blocking the activity of Epidermal Growth factor receptor (EGFR) have been developed and have shown clinical activity in patients with non-small cell lung cancer (NSCLC), pancreatic cancer, and colorectal cancer (CRC), and are in clinical development for a range of other solid tumors. The toxicity profile of such agents is characterized by a typica...
متن کاملEpidermal growth factor receptor (EGFR)-targeted therapies in esophagogastric cancer.
Esophageal and gastric cancer incidence has been increasing worldwide. Most cases are diagnosed in advanced stages, and current therapy has not been able to improve the modest survival rates after diagnosis. Epidermal growth factor receptor expression has been found to correlate with poor prognosis and aggressive disease in esophagogastric cancers. Targeting these receptors through monoclonal a...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Thoracic Oncology
سال: 2017
ISSN: 1556-0864
DOI: 10.1016/j.jtho.2016.11.158